Salute e Benessere
Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
(
The market's expansion is driven by a combination of regulatory reforms, new product approvals, and the shift toward simplified, pan-genotypic therapies. The adoption of for HBV continues to remain robust, while the transition to has transformed HCV care, reducing treatment durations from 24–48 weeks to as low as 8–12 weeks.
LSI keywords integrated:
Key growth factors influencing the 2024–2033 outlook include:
In 2024, the market remained dominated by , supported by the strong commercial performance of direct-acting antivirals. Of the total , HCV therapeutics accounted for approximately , representing of global revenues. This dominance is driven by high cure rates, short treatment durations, and aggressive payer funding to eradicate the disease burden.
Meanwhile, , accounting for of the market in 2024. Despite lower growth relative to HCV, HBV therapeutics benefit from lifelong treatment regimens, rising vaccination uptake, and increasing research activity in functional cure mechanisms such as siRNA-based therapies, capsid assembly modulators, and T-cell immune enhancers.
Oral formulations accounted for the largest share of the market in 2024, with revenues reaching
, equivalent to of global market value. The predominance of oral antivirals is linked to their effectiveness, patient convenience, and widespread availability across both retail and hospital channels.
Injectable therapeutics-including interferon-based therapy and novel immune-targeted biologics-represented
, or . Although historically declining, the segment has seen renewed interest in 2024 due to the development of long-acting immunotherapies for HBV functional cure programs.
Hospital pharmacies maintained a significant share of the market in 2024, contributing ( ) of total revenues as complex HCV regimens and high-risk HBV cases necessitated specialist intervention. Retail pharmacies accounted for ( ), supported by increased availability of DAAs through prescription-based community channels, especially in the U.S., Germany , and Japan .
The U.S. accounted for approximately , representing a market size of .
Key 2024–2025 quantitative drivers:
Japan represented approximately , translating to a . The country maintains one of the strongest national commitments to hepatitis elimination globally, reinforced by extensive universal screening and subsidized antiviral access.
Recent quantitative developments:
The competitive landscape remains dominated by global pharmaceutical leaders with extensive antiviral portfolios. Companies are investing aggressively in immune-targeting candidates, real-world evidence programs, and pan-genotypic innovation.
Within the hepatitis therapeutics category, Gilead, AbbVie, Merck, and Bristol-Myers Squibb remain highly dominant due to their strong patent portfolios, high cure rates, and extensive distribution networks.
The next decade will see a clear pivot toward functional cure strategies for HBV, an area where ongoing clinical trials involving siRNA therapies, core protein assembly modulators, and T-cell–directed immunotherapies show promising potential. The success of these new mechanisms could materially reshape the market landscape by reducing the burden of lifelong therapy, increasing compliance, and expanding the addressable patient population.
For HCV, the market will continue to mature with high cure rates, but opportunities remain in improving access across lower-income regions, integrating digital adherence systems, and expanding pan-genotypic RWE datasets.
As the global market approaches , companies with strong R&D investment, cost-optimized supply chains, and government-backed procurement agreements will maintain the strongest growth positions.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter , LinkedIn , and Facebook .
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hepatitis-b-and-c-therapeutics-market-surges-to-us17-02-billion-in-2024-as-innovation-national-screening-policies-and-next-gen-antivirals-transform-global-care--according-to-datam-intelligence-302620140.html